TPST
USDTempest Therapeutics Inc. Common Stock
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$7.025
Máximo
$7.230
Mínimo
$6.650
Volume
0.01M
Fundamentos da empresa
Capitalização de mercado
24.6M
Setor
Biotecnologia
País
United States
Estatísticas de negociação
Volume médio
0.06M
Bolsa de valores
NCM
Moeda
USD
Faixa de 52 semanas
Notícias relacionadas
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success
Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program.
Scotiabank Downgrades Tempest Therapeutics to Sector Perform, Lowers Price Target to $9
Scotiabank analyst George Farmer downgrades Tempest Therapeutics from Sector Outperform to Sector Perform and lowers the price target from $91 to $9.
HC Wainwright & Co. Downgrades Tempest Therapeutics to Neutral, Maintains Price Target to $16
HC Wainwright & Co. analyst Joseph Pantginis downgrades Tempest Therapeutics from Buy to Neutral and maintains the price target from $16 to $16.
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular carcinoma (HCC); global investigator support in placeAwarded both Orphan Drug & Fast Track
Ações relacionadas
PMCB
PharmaCyte Biotech Inc.
NVDA
NVIDIA Corporation
BFZ
BlackRock California Municipal Income Trust
NNE
Nano Nuclear Energy Inc.
GJS
Goldman Sachs Group Securities STRATS Trust for Goldman Sachs Group Securities Series 2006-2
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.